Management is buying the same thing twice: proven demand from one place is being replicated into identified new places r
The model's full reasoning — Q1 2016 call → NOWe need to determine if management describes a situation where a proven instance is being replicated now, with demand already visible at the destination. The key is: a specific piece of the business that works, and they are standing up more of it, with demand already there. Let's scan the transcript. Ed Breen mentions "our new long life Greek yogurts in China" and "Probiotics increased sales 30% as our productivity efforts have freed up capacity to respond to strong customer demand." That's about capacity freed up, not replicating a proven instance. Not that. Jim Collins talks about Ag: "we made our first sales of Zorvec fungicide" - that's a launch, not replication. "We successfully launched Leptra, insect protected corn hybrids in Brazil in the Safrinha season" - that's a launch, not replication. "we are currently introducing varieties with Roundup Ready 2 Xtend technology in a very limited launch" - that's a limited launch, not replication. What about the "agency based route to market approach in the Southern U.S. similar to the Advantage approach we take in the Midwest." That is a replication of a business model? Let's see: Jim says "we transition to an agency based route to market approach in the Southern U.S. similar to the Advantage approach we take in the Midwest." That is replicating a proven approach (Midwest) to Southern U.S. Is that a proven instance? The Midwest approach works. Are they standing it up now? Yes, transitioning. Is demand already visible? Not explicitly mentioned. Also, that is more of a distribution model change, not necessarily a new instance of a proven unit with demand waiting. Also, it's not described as large relative to company? It's a transition. Another possibility: "we are currently introducing varieties with Roundup Ready 2 Xtend technology in a very limited launch" - that's a product launch, not replication. What about "we announced our intention to commercialize our first corn hybrids, developed through the application of CRISPR-Cas advanced breeding technology within the five years." That's future, not now. What about "we made our first sales of Zorvec fungicide for disease control in Korea, Australia and China in the first quarter." That's a new product launch, not replication of a proven instance.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| VSEC | VSE Corporation | Q3 2022 | 2022-10-28 | B+ |
| FSLR | First Solar, Inc. | Q3 2022 | 2022-10-28 | C+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| GDS | GDS Holdings Limited | Q2 2021 | 2021-08-17 | C+ |
| TPIC | TPI Composites, Inc. | Q3 2018 | 2018-11-11 | C |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| FOLD | Amicus Therapeutics, Inc. | Q1 2018 | 2018-05-08 | C+ |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| VSAT | Viasat, Inc. | Q4 2017 | 2017-05-23 | C+ |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
GDS · Q2 2021 → YESThe question is whether management describes the company as currently in the middle of copying a part of its own business that is already working into additional places where the same demand is alread...YES The transcript shows management describing a clear, present-tense replication of their proven China-based data center platform into new markets (Hong Kong, Macau, Southeast Asia) where demand is already visible and committed. William Huang explicitly references the “proven” China edge-of-town model (land-and-expand MOUs, 500 000 sqm secured pipeline, hyperscale orders already landed) and states they are “currently developing two purpose-built data centers” in Hong Kong (HK1/HK2) with most capacity “already allocated to strategic customers pending contracts,” plus a new building (HK4) under agreement and a heads-of-agreement for HK3, creating “nearly 80 megawatts of purpose-built capacity through to 2027.” For Macau they have a JV to acquire brownfield sites for redevelopment (20 MW).
FOLD · Q1 2018 → YESThe question is about whether management describes the company as currently copying a proven part of its business into additional places where demand is already visible. YES The transcript shows management describing Galafold as a proven commercial offering (Q1 revenue $16.7M, 300% YoY growth, hundreds of patients, high compliance, 7 approvals, 18 countries with pricing/reimbursement) that is now being replicated into additional markets.
TPIC · Q3 2018 → YESThe question is whether management describes the company as currently in the middle of copying a part of its own business that is already working into additional places where the same demand is alread...YES The transcript shows management describing a proven manufacturing operation (existing dedicated lines and plants in the U.S.